Charming Medical Limited Class A Ordinary Shares
NASDAQ:MCTAMedical - Care Facilities
+$0.00 today
- Market cap
- $445.55M
- Beta
- 0.00
- P/E (TTM)
- 414.6
- EPS (TTM)
- $0.07
Volume 0.00M
Average 0.87M
Big Five Numbers
Charming Medical Limited Class A Ordinary Shares growth analysis
Start with the long-run numbers that show whether MCTA compounds: return on capital and growth in sales, earnings, equity, and free cash flow.
Big Five Numbers
CAGR by period · ROIC shows average
| Metric | 10yr | 5yr | 3yr | 1yr |
|---|---|---|---|---|
EPS | N/A | N/A | N/A | +54.2% |
Revenue | N/A | N/A | N/A | +3.4% |
Equity | N/A | N/A | N/A | N/A |
Cash | N/A | N/A | N/A | -61.2% |
ROIC | N/A | N/A | -142.8% | 95.9% |
Analysis
Latest growth is strongest in ROIC at 95.9% and weakest in Cash at -61.2%. Three-year average ROIC is -142.8%, which helps show whether that growth is being earned efficiently.
Growth analysis
Is growth accelerating or fading?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Revenue segments
Where does the growth come from?
Break revenue down by product and geography to see which parts of the business drive the trend.
Revenue by segment
Where MCTA earns its revenue, as reported in company filings
This company does not report revenue segments.
Free cash flow
Does growth turn into cash?
Check whether reported growth converts into free cash flow after capital spending.
Free Cash Flow
Net Income to FCF bridge
FY2024
Analysis
FY2024 free cash flow is $138.4K. FCF conversion is 11.5% of net income. Operating cash flow was $425.9K, with capex of -$287.5K. The largest bridge item is Working Capital at -$1.2M.
Price targets
What do analysts expect from the price?
Compare the current price with the low, average, and high analyst targets.
Wall Street price targets
1-year price history with analyst consensus target
Unlock analyst target range
Sign in free to see low, average, high targets and implied upside for MCTA.
Analyst ratings
How do analysts rate the stock?
Review the buy, hold, and sell split and recent upgrades and downgrades.
Analyst ratings
Buy, hold, and sell recommendations and recent rating changes
No analyst ratings available.
Competitor growth
How does Charming Medical Limited Class A Ordinary Shares grow against peers?
Compare historical and forecast growth with similar companies.
Competitor Growth
Peer CAGR comparison & forward estimates
| Company | Market Cap | 10yr | 5yr | 3yr | Fwd |
|---|---|---|---|---|---|
Agilon Health, Inc. AGL | $1.51B | — | +37.2% | +35.4% | +8.1% (5yr)5 analysts |
Annexon, Inc. ANNX | $614.41M | — | — | — | —6 analysts |
Tactile Systems Technology, Inc. TCMD | $535.50M | +18.0% | +12.0% | +10.1% | +9.2% (3yr)3 analysts |
The Oncology Institute, Inc. TOI | $512.91M | — | +21.8% | +25.8% | +29.4% (3yr)1 analysts |
Delcath Systems, Inc. DCTH | $500.36M | +47.5% | +120.2% | +215.3% | +22.2% (5yr)2 analysts |
Cross Country Healthcare, Inc. CCRN | $428.06M | +3.2% | +4.7% | -27.8% | +2.6% (5yr)1 analysts |
Simulations Plus, Inc. SLP | $374.16M | +15.8% | +13.7% | +13.7% | +8.1% (5yr)1 analysts |
RxSight, Inc. RXST | $208.80M | — | +55.7% | +40.0% | +2.5% (5yr)6 analysts |
Nakamoto Inc. NAKA | $131.71M | — | — | -21.7% | +257.2% (3yr)1 analysts |
Questions
Growth questions
Common questions about MCTA's growth, answered from reported and forecast figures.
Is MCTA growing revenue?
Revenue grew 3.4% year over year, from $6.02M to $6.22M.
Is MCTA turning growth into profit?
The latest net margin is 19.3%, which shows how much revenue became net income.
Continue the stock analysis
Jump to another research area for this company.